



**International  
Neurodegenerative Disorders  
Research Center**

**Annual Report  
2022**

## Content

<b>BASIC DATA ABOUT THE ORGANIZATION .....</b>	<b>3</b>
EXECUTIVE BOARD .....	3
DIRECTOR .....	3
SCIENTIFIC ADVISORY BOARD .....	4
<b>MISSION .....</b>	<b>5</b>
<b>VISION.....</b>	<b>6</b>
<b>INDRC IN MEDIA .....</b>	<b>7</b>
<b>EVENTS IN 2022 .....</b>	<b>8</b>
INDRC WORKSHOP & RECEPTION .....	8
INDRC CONFERENCE 2022 .....	8
CZECH-FRENCH AI WORKSHOP ON AI.....	11
THE YEAR 2022 IN SUMMARY .....	12
FINANCIAL CONTRIBUTIONS.....	12
<b>INDRC PARTNERS AND SUPPORTERS.....</b>	<b>13</b>
<b>BALANCE SHEET IN SHORTENED MODE .....</b>	<b>14</b>
<b>PROFIT AND LOSS STATEMENT.....</b>	<b>15</b>
<b>ANNEX TO THE FINANCIAL STATEMENTS FOR 2022.....</b>	<b>16</b>

## Basic data about the organization

Name	<b>International Neurodegenerative Disorders Research Center, z.ú.</b>
Headquarters	Evropská 2758/11, 160 00 Praha 6, Česká republika
Founder	Martin Tolar, MD
ID No.	11883383
Account number	6151333379/0800

## Executive Board

Chairman	<b>Martin Tolar, MD, PhD</b>
Board Members	Prof. Ing. Vladimír Mařík, DSc John Hey, PhD Pavel Hroboň, MD, MS Prof. Ing. Václav Snášel Milan Kulháněk Ing. Eva Troppová, PhD Ing. Jaroslav Lískovec Cezary Kaliszyk, PhD

## Director

Executive Director of INDRC	PhDr. Mgr. Vít Dočkal, PhD
-----------------------------	----------------------------

## Scientific Advisory Board

### **Ara S. Khachaturian, PhD – chairman**

Prof. Dr. rer. nat. Wolfgang Wahlster

Prof. Bruno Vellas, MD, PhD

Prof. Paolo Maria Rossini, MD

Joseph Lombardo

Rhoda Au, PhD

Michelle Mielke, PhD

Jakub Hort MD, PhD, FEAN

Research Assistant Professor Jean-Marie Charles Bouteiller, PhD

Kateřina Sheardová, MD, PhD

Michael W. Lutz, PhD

Ing. Josef Šivic, PhD

Prof. Robert Mikulík, MD, PhD

Zaven Khachaturian, PhD

Ira Haraldsen, MD, PhD

## Mission

The International Neurodegenerative Disorders Research Center, is a private, non-profit global research institute established to apply artificial intelligence (AI) and machine learning (ML) solutions to identify and develop treatments for Alzheimer's disease and other neurodegenerative diseases. The scientific institute was established in 2021 in Prague.

The aim of the institute is to build a multidisciplinary technology platform for the development of breakthrough treatments based on the use of AI to process large amounts of data and information about normal function and diseases of the human brain.

The search for effective treatments remains extremely slow, largely due to a lack of understanding of the complex interrelationships between brain structure, function and disorders.

Therefore, the organization is focusing on these problems:

1. Understanding the complex relationship between the structure and function of the human brain
2. Limited knowledge of the pathogenic pathways that damage or destroy neurons and their connections
3. Lack of applications of artificial intelligence and machine learning solutions to study the function and information processing of the healthy and diseased human brain

## Vision

INDRC's vision is to become the leading international non-profit research centre for Alzheimer's disease and other neurodegenerative diseases.

INDRC aims to bring together and develop globally fragmented knowledge through fellowship programs of excellence, to provide cutting-edge independent research programs, to build a world-class research scientific community, and to enable technological and therapeutic innovations with real impact on society and humanity.

To connect experts in the fields of neuroscience, machine learning and artificial intelligence.

With the financial support of partners, including private and individual donors, INDRC is able to develop multidisciplinary links between medicine and IT in an effort to understand and then effectively treat neurodegenerative diseases of the human brain.

## INDRC in media

Selected press releases:



Forbes: Artificial intelligence will protect our brains. The Prague conference will present new weapons in the fight against Alzheimer's

### **FORBES**

August 26, 2022

**„Našim mozgům pomůže umělá inteligence. Pražská konference představí zbraně i proti Alzheimerovi“**

<https://forbes.cz/nasim-mozkum-pomuze-umela-intelligence-prazska-konference-predstavi-zbrane-i-proti-alzheimerovi/>



Artificial intelligence to defeat brain degeneration? The world leaders in Alzheimer's research and artificial intelligence will for the first time meet in the Czech Republic

### **SEZNAM ZPRÁVY**

August 28, 2022

**„Umělou inteligencí proti chátrání mozku? Špičky oboru se sejdou v Česku“**

<https://www.seznamzpravy.cz/clanek/domaci-zivot-v-cesku-umelou-inteligenci-proti-chatrani-mozku-spicky-oboru-se-sejdou-v-cesku-212632>



Experts on artificial intelligence and Alzheimer's disease from EU and US will meet for the first time in Prague

### **EKONOMICKÝ MAGAZÍN**

August 27, 2022

**„Experti na umělou inteligenci a Alzheimerovu nemoc z EU a USA se poprvé potkají v Praze“**

<https://e-news.cz/aktuality/experti-na-umelou-inteligenci-a-alzheimerovu-nemoc-z-eu-a-usa-se-poprve-setkaji-v-praze/>

## Events in 2022

### INDRC Workshop & Reception

March 10, 2022

### INDRC Conference 2022

September 7 – 8, 2022

AI Solutions for Understanding & Treatment of Neurodegenerative Disorders



Organized by:



Co-organized by:



The conference brought a completely unique intersection and connection of two scientific worlds - experts in biological sciences and medicine discussed with experts in artificial intelligence and big data. Subsequently, they began to jointly develop new ways of human brain understanding.

The conference was held under the auspices of the Minister for European Affairs of the Czech Republic, doc. Mikuláš Bek, PhD, Deputy Prime Minister for Digitalization and Minister for Regional Development Ivan Bartos, PhD, the US Embassy in the Czech Republic and the City of Prague, as an official side event of the Czech EU Presidency.

In addition to INDRC, the co-organizers were: the American company Alzheon, Inc. and the Czech Institute of Informatics, Robotics and Cybernetics of the Czech Technical University in Prague (CIIRC CTU).



### **Partners of the Conference:**

- Zebra Technologies
- Deloitte
- Česká spořitelna
- Zdravotní pojišťovna Ministerstva vnitra ČR
- Vojenská zdravotní pojišťovna České republiky

### **Main media partner of the Conference:**

- Česká televize®

### **Aims of the Event:**

To hold the first joint meeting of the world's leading US and EU experts in the fields of:

- Neuroscience
- Medicine and Clinical Research
- Natural Sciences
- Artificial Intelligence
- IT Science and Engineering
- Unique interdisciplinary platforms

### **To create a unique multidisciplinary technological platform for:**

- Scientists
- Interested companies
- Entrepreneurs
- Politicians
- Investors
- Private Equity & JV Capital Funds

### **Main outcomes of the Conference:**

- Establishing new interdisciplinary partnerships
- Intercontinental scientific cooperation
- Regular scientific meetings, including online meetings
- Exchange of experience and knowledge in the fields of: medicine, neuroscience, clinical research, artificial intelligence, machine learning, informatics and computing, etc.
- Linking biotechnology and artificial intelligence
- Increase in the number of collaborating scientists, leaders in their fields
- The establishment of specific scientific projects at the Institute
- Popularisation of neurodegenerative diseases, in particular Alzheimer's disease

### **Speakers:**

Ing. Jozef Síkela, Minister of Industry and Trade of the Czech Republic

Roman Kraus, MD, Committee on Health, Senate of the Czech Republic

Martin Tolar, MD, PhD, Chairman of INDRC Executive Board, President & CEO of Alzheon Inc.

Vít Dočkal, PhD, INDRC Director

Ara S. Khachaturian, PhD, Chairman of the INDRC Scientific Advisory Board, NBREC

Prof. Vladimír Mařík, Scientific Director, CIIRC CTU Prague

John Hey, PhD, Chief Scientific Officer, Alzheon, INDRC Executive Board member

Prof. Jacques Touchon, MD, PhD, University of Montpellier, France

Sundar Subramaniam, Chairman of IBCC Capital Management, Chairman of Knome & Sialix

Stanislav Fořt, PhD, Research Scientist at Anthropic, Inc. USA

Research Associate Prof. Jean-Marie Bouteiller, PhD, University of Southern California, USA

Everard (Jort) Vijverberg, MD, PhD, Amsterdam UMC Dept. of Neurology

Petr Kočiš, PhD., Founder @ CEO Biopharmatica, Fmr. Global Head of Drug Discovery Sciences @Technologies

Prof. Virend Somers, MD, PhD, Mayo Clinic, USA & Associate

Prof. Tomáš Kára, MD, Mayo Clinic, USA & Brno Municipal Hospital of Merciful Brothers,

## Czech-French AI Workshop on AI

September 12 -13, 2022

Vít Dočkal, PhD, Director of INDRC, presented the vision of INDRC, z.ú.

The Czech-French workshop on artificial intelligence was jointly organized by the Ministry of Foreign Affairs of the Czech Republic, the French Embassy in Prague, the Czech Institute of Informatics, Robotics and Cybernetics of the Czech Technical University in Prague and Inria with the support of other partners.

The aim of the event was to bring together leading experts from various fields of artificial intelligence, entrepreneurs and representatives of political representation. The event was a platform for connecting key players active in the development and application of digital technologies and AI. The workshop also included a high-level session with key stakeholders.



## Fulfilling the objectives

We have managed to establish cooperation on both professional and commercial levels with 10 Czech institutions, one foreign University and one foreign Institute.

Considering the period of INDRC's operation, this was a positive development with further potential for the future.

All Statutory Partners and Partner were actively involved in the development of the institute and its activities.

## The year 2022 in summary

- Commencement of activities of the authorities of the registered institute: Executive Board, Assembly, Scientific Advisory Board
- Gradual expansion of the members of the Scientific Advisory Board
- Setting up the accounting, personnel and legal agenda of the Institute
- Identifying active partners and supporters of the Institute
- Selection procedure for the post of Director of the Institute
- Preparation of the Director's agenda handover

## Financial contributions

In 2022, financial contributions were received for the running and development of the Institute, as well as for the organization of the INDRC Conference 2022 in the total amount of CZK 1.792.000.

## INDRC Partners and Supporters

### Statutory partners



### Partners



VSB - Technical University Ostrava

### Hospitals, Associations, Foundations



University Hospital in  
Motol in Prague



International Clinical Research  
Center of St. Anne's University  
Hospital in Brno



Czech National Institute of  
Mental Health

**a...**

Česká  
alzheimerovská  
společnost

Czech Alzheimer Society

### Institutions and Universities



Institute of Organic Chemistry and  
Biochemistry of Czech Academy of  
Sciences



J. Heyrovsky Institute of  
Physical Chemistry of Czech  
Academy of Sciences



NUDZ National  
Institute of Mental  
Health



RECETOX Research Center  
of Masaryk University in  
Brno



Czech Institute of  
Informatics, Robotics, and  
Cybernetics of Czech  
Technical University in  
Prague



Center for Economic  
Research and Graduate  
Education – Economics  
Institute of Charles  
University in Prague



Vrije Universiteit Amsterdam



German Research Center  
for Artificial Intelligence

## Balance sheet in shortened mode

As at December 31, 2022, in whole thousands CZK

ID No.: 11883383

Label a	ASSETS b	Status at the first day of the accounting period 1	Status at the last day of the accounting period 2
<b>B.</b>	<b>Short-term assets total</b>	206	586
B.I.	Inventories total	0	0
B.II.	Receivables total	200	381
B.III.	Short-term financial assets total	6	197
B.IV.	Other assets total	0	7
<b>ASSETS TOTAL</b>		<b>206</b>	<b>585</b>

Label a	PASSIVE b	Status at the first day of the accounting period 3	Status at the last day of the accounting period 4
<b>A.</b>	<b>Own resources total</b>	206	569
A.I.	Equity total	250	666
A.II.	Economic result total	-44	-97
<b>B.</b>	<b>External resources total</b>	0	16
B.III.	Short-term payables total	0	16
<b>PASSIVE TOTAL</b>		<b>206</b>	<b>585</b>

## Profit and loss statement

For non-profit organisations in full, as of December 31, 2022

ID No.: 11883383

Label a	COSTS b	Activity		
		main 1	economic 2	total 3
A.I.	Purchases and services consumed	1.776	0	1.776
A.II.	Changes in inventories of own operations and capitalisation	0	0	0
A.III.	Personal costs	95	0	95
A.IV.	Taxes and fees	0	0	0
A.V.	Other costs	28	0	28
A.VI.	Depreciation, assets sold, creation and use of provisions and valuation allowances	0	0	0
A.VII.	Contributions provided	0	0	0
A.VIII.	Income tax	0	0	0
<b>COSTS TOTAL</b>		<b>1.889</b>	<b>0</b>	<b>1.889</b>

Label a	REVENUES b	Activity		
		main 1	economical 2	total 3
B.I.	Operational subsidies	150	0	150
B.II.	Contributions received	87	0	87
B.III.	Revenue from own performance and goods	1.554	0	1.554
B.IV.	Other revenues	1	0	1
B.V.	Revenues from the sale of assets	0	0	0
<b>REVENUES TOTAL</b>		<b>1.792</b>	<b>0</b>	<b>1.792</b>
C.	Profit before tax	-97	0	-97
D.	Profit after tax	-97	0	-97

## Annex to the financial statements for 2022

**Accounting entity:** International Neurodegenerative Disorders Research Center, z.ú.

**ID No.:** 11883383

### **Notes:**

1. *Values are stated in thousands of CZK, unless the entity decides otherwise in individual cases.*
2. *The information in the notes is based on accounting records and other documentation available to the entity*
3. *The notes to the financial statements are prepared in accordance with the Accounting Act No. 563/1991 Coll., as amended, and in particular with the implementing Decree No. 504/2002 Coll.*

### **GENERAL INFORMATION**

Basic information about the accounting entity:

Name of accounting entity	<b>International Neurodegenerative Disorders Research Center, zapsaný ústav</b>
Headquarters	<b>Evropská 2758/11, 160 00 Praha 6, Czech republic</b>
Legal form	Registered Institute
<b>Purpose of the registered institute</b> in its entirety as registered in the Commercial Register	<b>Independent interdisciplinary research on neurodegenerative diseases and related aspects and support for the development of scholarship, research excellence and innovation in the field, including technology transfer</b>
Date of establishment of the entity or date of commencement of operations	<b>September 27, 2021</b>

The individuals or legal entities that established the institute:

<b>Person</b>	<b>Date</b>
MUDr. Martin Tolar, Ph.D.	Sept. 27, 2021
prof. Ing. Vladimír Mařík, DrSc., dr. he.	Sept. 27, 2021
MUDr. Pavel Hroboň, M.s.	Sept. 27, 2021
PhDr., Mgr. Vít Dočkal, Ph.D.	Sept. 27, 2021
Ing. Eva Troppová, Ph.D.	Sept. 27, 2021



Names and surnames of the statutory or supervisory authorities or their members at the balance sheet date:

Person	Function
PhDr., Mgr. Vít Dočkal, Ph.D.	Executive director
MUDr. Martin Tolar, Ph.D.	Chairman
prof. Ing. Vladimír Mařík, DrSc., dr. he.	Member of EB
MUDr. Pavel Hroboň, M.s.	Member of EB
Ing. Jaroslav Lískovec	Member of EB
Ing. Eva Troppová	Member of EB

A description of the organisational structure of the entity and its significant changes during the accounting period: The Institute was founded and established on September 27, 2021 by registration in the Commercial Register. The purpose of the Institute is to carry out publicly beneficial activities in the field of independent interdisciplinary research in the field of neurodegenerative diseases and to support the development of education, research excellence and innovation in the field, including technology transfer.

## INFORMATION ON ACCOUNTING METHODS, GENERAL ACCOUNTING PRINCIPLES AND VALUATION TECHNIQUES:

Method of valuation of *purchased inventories*: no filling

Method of valuation of *own-produced inventories*: not applicable

Valuation method for internally generated *intangible fixed assets*: not applicable

Valuation method for *securities and shares*, derivatives and the part of assets and liabilities secured by derivatives: not applicable

Method of determining the *replacement cost of assets measured at that cost* and acquired during the accounting period: not applicable

The types of *acquisition-related costs* included in the cost of inventories purchased and the types of costs included in the cost of *inventories* determined at cost level: not applicable

Significant changes in *valuation, depreciation and accounting policies* -there were no changes in valuation methods or accounting policies during the financial year

Method of determining the *valuation allowance*, indicating the source of information for determining the amount of the valuation allowance: not applicable

The method of preparing *depreciation schedules for fixed assets* (accounted for in accounting class 0) and the depreciation methods used in determining depreciation: not applicable

Method applied in the *conversion of foreign currency data into Czech currency* (application of exchange rates announced by the CNB as current or fixed rates with indication of the dates of their changes): the Institute uses the actual exchange rates announced by the CNB at the date of the accounting case

Method of determining the *fair value of assets and liabilities* measured at fair value in accordance with the law: not applicable

## **SUPPLEMENTARY INFORMATION TO THE BALANCE SHEET AND PROFIT AND LOSS ACCOUNT:**

Schedule of tangible assets encumbered by a lien or, in the case of immovable property, an easement, indicating the nature and form of the security: not applicable

Aggregate amount of *overdue receivables*; data are taken from the relevant analytical accounts: not applicable

Aggregate amount of *overdue liabilities*; data are taken from the relevant analytical acnts: 6

Liabilities covered by a pledge, indicating the nature and form of the collateral in the event of default: not applicable

*Závazky (peněžní i nepeněžní) nevyúčtované v účetnictví a neuvedené v rozvaze, např. záruky přijaté za jiný podnik z titulu bankovního úvěru nebo směnečného práva, pokud nebyly proúčtovány ve formě peněžních rezerv: není náplň*

*Equity holdings*: not applicable

Result: the financial results of the main activity were closed with a loss of CZK 44 thousand. This was only the costs related to the establishment of the Institute

*Data on employees*: the institute employs 1 employee on a work performance agreement

*Taxes*: in accordance with the Income Tax Act (Section 18a(5) of the Income Tax Act, broad-based taxation), as amended, and the profit and loss account for the financial year 2022, the entity is not required to pay income tax.

*Subsidies*: the institute was granted a special purpose operating subsidy No. DOT/62/03/009862/2022 in the amount of CZK 150,000, provided by the City of Prague

*Donations*: the entity received the following donations during the financial year:

Entity	ID No.	Amount
Brněnské komunikace a.s.	60733098	CZK 50.000
Ing. Ivan Točev, MBA		CZK 7.000
RP consultants, s.r.o.	04181824	CZK 30.000

*Deposits of Statutory Partners:*

Entity	ID No.	Amount
CertiCon a.s.	25083341	CZK 50.000
TRIX Connections, s.r.o.	28417976	CZK 50.000
Deloitte Advisory s.r.o.	27582167	CZK 50.000
Alzheon. Inc.	46-3074149	CZK 50.000